The identification of prostate cancer remains problematic; no single, simple procedure exists for a reliable diagnosis. Prostate specific antigen (PSA), while non-invasive and easily measurable in serum, is not specific owing to false-positives from benign prostatic hyperplasia (BPH), inflammatory conditions and prostatic trauma. Additional diagnostic information must therefore be obtained by transrectal ultrasonography (TRUS) and digital rectal examination (DRE) to assess prostate size and morphology. Final confirmation of a malignancy requires histopathological analysis of several biopsies. A remaining hurdle in the identification process is the existence of indolent organ-confined disease and aggressive metastatic prostate cancer that can only be distinguished by additional imaging or nuclear medicine procedures.
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In a new approach to this diagnostic dilemma, it has been argued that screening for changes in metabolite expression resulting from gene silencing and gene activation could be used to identify a specific biological marker that increases in the transformation process. Therefore, a paper elaborating on metabolite expression in clinical samples of benign, localised and metastatic prostate cancer 1 was enthusiastically received and debated in editorials. [2] [3] [4] [5] The proposal that sarcosine (N-methylglycine) (a metabolite of choline found in urine) may be characteristic for prostate cancer progression has since been examined in other laboratories. 1 These investigations found sarcosine levels in urine 6 and serum 7 to be constant, irrespective of sample pathology. From our own and published preliminary measurements, it is nevertheless clear that sarcosine-alanine ratios in prostate tumour patients are often elevated above controls and are spread over a wider range. 1, 7, 17 A relationship between sarcosine and disease therefore cannot as yet be totally ruled out. Interest in sarcosine as a marker molecule remains topical, as shown by a recent modification of sarcosine assay by GC/MS in urine. 8 We present measurements in plasma of prostate cancer patients characterised by PSA, tumour stage and Gleason score using GC/MS for sarcosine methodology 9, 10 to elaborate further on the suitability of sarcosine as a marker for prostate cancer.
Methods
Patient blood was collected by venipuncture and centrifuged, and clear supernatants were stored at -20°C. The AxSYM total PSA was determined by a MEIA microparticle enzyme immune assay (Abbott) and expressed as ng/ml. Ethical approval was granted by the University of Stellenbosch Health Research Ethics Committee (N09/11/330).
Sarcosine and alanine were quantified in plasma by gaschromatograph mass spectrometry. Briefly, amino acids were extracted from 100 µl of acidified plasma by solid phase extraction onto a cation exchange column before being washed, eluted and derivatised to their corresponding alkyl chloroformates using a commercial kit (EZ:faast, Phenomenex, Torrance CA, USA). After derivatisation, the amino acids were extracted into solvent and 2 µl injected into an Agilent 7890A/5975C GCMS system fitted with a Zebron ZB AAA 10 m x 0.25 mm capillary GC column. The sample Introduction. Diagnosis of prostate cancer by prostate specific antigen (PSA) is error-prone and cannot distinguish benign prostatic hyperplasia (BPH) from malignant disease, nor identify aggressive and indolent types. Methods. We determined serum sarcosine (N-methylglycine) in 328 cancer patients by gas chromatography (GC)/mass spectroscopy (MS) and searched for correlations with early (stage T1/T2) and advanced (stage T3/T4) disease.
Results. Serum sarcosine of male control patients ranged from 1.7 µmol/l to 4.8 µmol/l. In prostate cancer patients, sarcosine ranged from 2.8 µmol/l to 20.1 µmol/l. Expressed as the sarcosine/alanine ratio, serum control values were 9.4±5.5x10 -3 (mean±SD) compared with 21.6±9.0; 28.5±16.6; 22.7±7.7 and 22.2±11.0 for patients diagnosed with T1, T2, T3 and T4 prostate tumours, respectively. The small differences between T1, T2, T3 and T4 patients were not statistically significant (p=0.51). However, the conventional PSA marker significantly correlated with T stage in these patients (r=0.63; p<0.009).
Conclusions. The median sarcosine/alanine ratios among patients with early and advanced prostatic cancer ranged from 21.6±9.0 to 28.5±16.6 and were fairly constant, showing no statistically significant differences between T-stages. The results are consistent with published data in urine and serum which find differences between controls and patients with metastatic prostate cancer to be small and sarcosine to be uninformative regarding prostate cancer progression. By multi-comparison of PSA with T-stages in the same group of patients, we found significant correlations confirming the well-known merits and limitations of this marker.
was injected at a 1:10 split and 250°C. Helium was used as the carrier gas at 1.65 ml/min, and the column heated from 110°C to 320°C at 30°C per minute. The amino acids were quantified using a norvaline internal standard against standard curves generated from traceable calibrators using the following ions and (qualifier ions): alanine -mz 130, sarcosine -mz 217, and norvaline -mz 158. Fig. 1 demonstrates a total ion chromatogram obtained from an equimolar 20 µmol/l solution of amino acids. Abundance of alanine in plasma was used as the internal reference, and all results were expressed as the sarcosine/ alanine ratio, as previously suggested.
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Results
Absolute sarcosine levels in serum/plasma of male control patients were found to be in the range of 1.7 -4.8 µmol/l while alanine used as the internal standard was in the range of 301 -553 µmol/l. To circumvent variations owing to diet and metabolic factors, sarcosine is now commonly expressed as the sarcosine/alanine ratio. The median sarcosine/alanine ratios in tumour patients were fairly constant and in the range of 15 -25 x10 -3 . Within a given tumour category, e.g. T2, sarcosine/alanine ratios can vary by factors as high as 10, while the median sarcosine/alanine ratios in early and advanced tumours remain in a fairly narrow range of 15 -25 x10 -3 with a trend towards lower values in the T3/T4 group of tumors (Fig.  2) . The sarcosine results were obtained in plasma of patients who had undergone transurethral resection (TURP) to alleviate urinary obstruction. Of these patients, 27% had benign prostatic hyperplasias (BPH) and were not entered for sarcosine analysis. Samples entered for sarcosine determination fell into 2 groups: tumour stages T1 and T2, Gleason score <7; and advanced tumours T3 and T4 with a Gleason score >7. Fig. 2 shows sarcosine/alanine ratios in the T1/T2 group of patients to be higher than in the T3/T4 group of patients. Two-tailed multiple comparison of sarcosine/alanine ratios with T-stages by Kruskal-Wallis multiple comparison test dialogue indicated that the differences between medians were not statistically different (p=0.51).
Examining the relationship between tumour stage and PSA in a larger contingent of patients (N=325), we found PSA to be well below 200 ng/ml for the T1 and T2 group of patients, reaching 1 200 ng/ml in the T3 and T4 group of patients. PSA and T stage were significantly correlated (r=0.63 and p<0.009). Data for percentage free PSA were not available in our patients. By Kruskal-Wallis multiple comparison, we found that the PSA in T1 patients differed significantly from T3 and T4, and T2 differed from T4, while PSA did not separate T2 from T3 and T1 from T2 (Table 1, Fig. 3 ).
Discussion
Using urine samples, Jentzmik et al. found the sarcosine/creatinine ratios in patients with prostatectomy-based Gleason score <7 and Gleason score >7 not to be statistically different. 6 Since sarcosine in urine is due to renal excretion, urine may not be a representative body fluid. 6 Therefore, plasma may be a better source of abnormal metabolite expression. Following this reasoning, Struys et al. determined sarcosine in plasma from controls, localised prostate cancer, and metastatic castration-resistant prostate cancer. In this study, the mean sarcosine concentration was found to be at the level of 2.0 µmol/l with no statistical differences between the 3 sample categories. 7 Our results (Fig. 2) are consistent with the findings on urine 6 and serum 7 and show that, where prostate cancer is manifest, the sarcosine/alanine ratio cannot distinguish early and advanced disease. Specific alterations of sarcosine metabolism exist in folate and in N-methylglycine-transferase deficiency where sarcosine reaches levels as high as 49.3 µmol/l. 13 Jentzmik et al. pointed out in their analysis of urine sediments 6 that the sarcosine/creatinine ratios were insensitive to rectal palpation, in contrast with Sreekumar's original findings 1 that observed such sensitivity. That sarcosine correlates with invasion and performs better than PSA to distinguish diagnostic classes in the grey zone of 2 -10 ng/ml PSA 1 also could not be corroborated. 6 The controversy about sarcosine as a new diagnostic marker has been debated in an editorial 14 and several letters. [15] [16] [17] [18] A consistent observation in our analysis is that the sarcosinealanine ratios within patient groups can vary as much as 10 times, e.g. in T2 patients (Fig. 2) . The median T1, T2, T3 and T4 ratios were found to be in the range of 15 -25x10 -3 and to be fairly constant, showing no statistically significant differences. Publications on urine sediments showed sarcosine-alanine ratios to be higher than in serum and to vary from 70x10 -3 in controls to 100x10 -3 in prostate cancer patients, and a 2 -3 times variation of ratios within groups. 17 From our data, we conclude that sarcosine has little merit as a biomarker and can give no useful additional information on prostate cancer progression. Also not supported is proof of the concept of sarcosine as a potential biomarker put forward in the exchange of views on sarcosine. 17 The failure of sarcosine as a marker for prostate cancer prompted us to re-examine the diagnostic merits of PSA, using data from our teaching hospital at Tygerberg. PSA separates the T1 -T2 from the T3 -T4 group of tumours rather well (Fig. 3, Table 1 ). These results are in agreement with extensive PSA data showing that mean and median PSA values indeed differ between T-stages where they serve as a valuable indicators in the management of the disease. 19, 20 Our results add to the growing realisation that sarcosine as a potential biomarker of prostate cancer progression may not live up to expectations.
